Patient-reported outcomes (PROs), which assess symptoms, functional status, and quality of life, had independent prognostic value for overall survival in patients with cancer, according to a ...
Management of Malignant Pleural Effusion in 2024: A Definitive and Unified Global Approach Interestingly, though, the Danish multicenter randomized study 6 did not reproduce the survival benefit ...
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study This multicenter open-label RCT enrolled ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
The study's safety findings suggest that the physical "number" of a patient's age is less important than their functional ...
The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The ...
A large multinational clinical trial has found that giving healthcare providers access to European Organisation for Research and Treatment of Cancer (EORTC) patient-reported outcome (PRO) data ...
Access to patient-reported outcome (PRO) data significantly improved providers' consistency in assessing adverse events in patients with cancer, with the greatest improvements observed for ...
The care that older adults with advanced cancer receive often does not align with their preferences and values, study ...
Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin ...
3don MSN
Health rounds: Genetic testing improves treatment, survival for Black breast cancer patients
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...
In the phase 2 ETOP ADEPPT trial, researchers sought to determine whether adagrasib, a KRAS G12C inhibitor, was effective in older patients and those with ECOG PS 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results